The nature of the drugs used to prevent that the rejection of kidney transplantation touched the body not the risk of cancer, a new study finds.
Kidney transplant patients have an increased risk of cancer, probably due to the long-term immunosuppressive drugs to prevent patients to rejection of the organ. In this study, the Australian researchers on the impact of cancer in 481 kidney transplant patients.
Patients had received one of the three regimes of treatment: azathioprine and prednisolone. Cyclosporine monotherapy; or Cyclesoporine as a single agent, followed by a switch azathioprine and prednisolone after three months.
In the 1920s after transplantation, 226 patients developed at least a cancer, including 48% who developed cancer of the skin and 27%, which has developed the non-skin cancer. None of the anti-rejection treatments had a greater effect than others on the calendar of the cancer or the effects.
The results show that "differences in the risk of these various treatments probably not clinically significant", study author Martin Gallagher said the George Institute for international health in Australia.
He and his colleagues have also found that an increased risk of cancer of the kidney transplant recipients at the time of the transplant by certain characteristics is shaped. For example, skin cancer is not connected with increasing age and history of smoking, while cancer of the skin ages, the color of the eyes is associated with not-Brun, light skin and a transplant operation.
Said patients at high risk should be more closely monitored, and use preventive measures to protect against cancer, the researchers.
The study is published in the issue of the journal of the American Society of Nephrology on 29 April.